Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron

Infection and Immunity

Volumn 75, Issue 7, 2007, Pages 3478-3489

  Slepenkin, Anatoly ^a   Enquist, Per Anders ^b   Hägglund, Ulrik ^c   De La Maza, Luis M ^a   Elofsson, Mikael ^b   Peterson, Ellena M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UMEÅ UNIVERSITY   (Sweden)

^c Innate Pharmaceuticals AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; APOTRANSFERRIN; DIVALENT CATION; FERRIC CHLORIDE; FERROUS SULFATE; HOLOTRANSFERRIN; INP 0341; INP 0400; IRON; METAL ION; TRANSFERRIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; COPB GENE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; GENE EXPRESSION; HUMAN; HUMAN CELL; INCA GENE; LCRH 1 GENE; NONHUMAN; PRIORITY JOURNAL; TYPE III SECRETION SYSTEM;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CELL LINE; CHLAMYDIA TRACHOMATIS; CHLAMYDIACEAE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, BACTERIAL; HELA CELLS; HUMANS; HYDRAZONES; IRON; MICROBIAL SENSITIVITY TESTS;

EID: 34447270306     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00023-07     Document Type: Article

References (33)

1. Al-Younes, H. M., T. Rudel, V. Brinkmann, A. J. Szczepek, and T. F. Meyer. 2001. Low iron availability modulates the course of Chlamydia pneumoniae infection. Cell. Microbiol. 3:427-437.
2. Bailey, L., S. Gylfe, C. Sundin, S. Muschiol, M. Elofsson, P. Nordstrom, B. Henriques-Normark, R. Lugert, A. Waldenstrom, H. Wolf-Watz, and S. Bergstrom. 2007. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett. 581:587-595.
3. Clifton, D. R., K. A. Fields, S. S. Grieshaber, C. A. Dooley, E. R. Fischer, D. J. Mead, R. A. Carabeo, and T. Hackstadt. 2004. A chlamydial type III translocated protein is tyrosine-phosphorylated at the site of entry and associated with recruitment of actin. Proc. Natl. Acad. Sci. USA 101:10166-10171.
4. de la Maza, L. M., J. M. Goebel, C. W. Czarniecki, and E. M. Peterson. 1984. Ultrastructural analysis of the growth cycle of Chlamydia trachomatis in mouse cells treated with recombinant human alpha-interferons. Exp. Mol. Pathol. 41:227-235.
5. de la Maza, L. M., E. M. Peterson, L. E. Burton, P. W. Gray, E. Rinderknecht, and C. W. Czarniecki. 1987. The antichlamydial, antiviral, and antiproliferative activities of human gamma interferon are dependent on the integrity of the C terminus of the interferon molecule. Infect. Immun. 55: 2727-2733.
6. de la Maza, L. M., E. M. Peterson, C. W. Fennie, and C. W. Czarniecki. 1985. The anti-chlamydial and anti-proliferative activities of recombinant murine interferon-gamma are not dependent on tryptophan concentrations. J. Immunol. 135:4198-4200.
7. de la Maza, L. M., M. J. Plunkett, E. J. Carlson, E. M. Peterson, and C. W. Czarniecki. 1987. Ultrastructural analysis of the anti-chlamydial activity of recombinant murine interferon-gamma. Exp. Mol. Pathol. 47:13-25.
8. Fields, K. A., E. R. Fischer, D. J. Mead, and T. Hackstadt. 2005. Analysis of putative Chlamydia trachomatis chaperones Scc2 and Scc3 and their use in the identification of type III secretion substrates. J. Bacteriol. 187:6466-6478.
9. Fields, K. A., D. J. Mead, C. A. Dooley, and T. Hackstadt. 2003. Chlamydia trachomatis type III secretion: evidence for a functional apparatus during early-cycle development. Mol. Microbiol. 48:671-683.
10. Hsia, R. C., Y. Pannekoek, E. Ingerowski, and P. M. Bavoil. 1997. Type III secretion genes identify a putative virulence locus of Chlamydia. Mol. Microbiol. 25:351-359.
11. Kalinowski, D. S., and D. R. Richardson. 2005. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 57:547-583.
12. Kauppi, A. M., R. Nordfelth, U. Hagglund, H. Wolf-Watz, and M. Elofsson. 2003. Salicylanilides are potent inhibitors of type III secretion in Yersinia. Adv. Exp. Med. Biol. 529:97-100.
13. Kauppi, A. M., R. Nordfelth, H. Uvell, H. Wolf-Watz, and M. Elofsson. 2003. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem. Biol. 10:241-249.
14. Matsumoto, A., and G. P. Manire. 1970. Electron microscopic observations on the effects of penicillin on the morphology of Chlamydia psittaci. J. Bacteriol. 101:278-285.
15. Mouralian, C., J. L. Buss, B. Stranix, J. Chin, and P. Ponka. 2005. Mobilization of iron from cells by hydroxyquinoline-based chelators. Biochem. Pharmacol. 71:214-222.
16. Muschiol, S., L. Bailey, A. Gylfe, C. Sundin, K. Hultenby, S. Bergstrom, M. Elofsson, H. Wolf-Watz, S. Normark, and B. Henriques-Normark. 2006. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc. Natl. Acad. Sci. USA 103: 14566-14571.
17. Nordfelth, R., A. M. Kauppi, H. A. Norberg, H. Wolf-Watz, and M. Elofsson. 2005. Small-molecule inhibitors specifically targeting type III secretion. Infect. Immun. 73:3104-3114.
18. Ossewaarde, J. M., A. de Vries, T. Bestebroer, and A. F. Angulo. 1996. Application of a Mycoplasma group-specific PCR for monitoring decontamination of Mycoplasma-infected Chlamydia sp. strains. Appl. Environ Microbiol. 62:328-331.
19. Peterson, E. M., X. Cheng, Z. Qu, and L. M. de la Maza. 1996. Characterization of the murine antibody response to peptides representing the variable domains of the major outer membrane protein of Chlamydia pneumoniae. Infect. Immun. 64:3354-3359.
20. Peterson, E. M., L. M. de la Maza, L. Brade, and H. Brade. 1998. Characterization of a neutralizing monoclonal antibody directed at the lipopolysaccharide of Chlamydia pneumoniae. Infect. Immun. 66:3848-3855.
21. Peterson, E. M., G. M. Zhong, E. Carlson, and L. M. de la Maza. 1988. Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity. Infect. Immun. 56:885-891.
22. Ponka, P., J. Borova, J. Neuwirt, and O. Fuchs. 1979. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 97:317-321.
23. Ratledge, C., and L. G. Dover. 2000. Iron metabolism in pathogenic bacteria. Annu. Rev. Microbiol. 54:881-941.
24. Raulston, J. E. 1997. Response of Chlamydia trachomatis serovar E to iron restriction in vitro and evidence for iron-regulated chlamydial proteins. Infect. Immun. 65:4539-4547.
25. Scidmore, M. A., and T. Hackstadt. 1995. Ability of Chlamydia trachomatis to obtain iron from transferrin, abstract D-161, p. 277. Abstr. 95th Gen. Meet. Am. Soc. Microbiol. 1995. American Society for Microbiology, Washington, DC.
26. Shaw, E. I., C. A. Dooley, E. R. Fischer, M. A. Scidmore, K. A. Fields, and T. Hackstadt. 2000. Three temporal classes of gene expression during the Chlamydia trachomatis developmental cycle. Mol. Microbiol. 37:913-925.
27. Slepenkin, A., L. M. de la Maza, and E. M. Peterson. 2005. Interaction between components of the type III secretion system of Chlamydiaceae. J. Bacteriol. 187:473-479.
28. Slepenkin, A., M. Elofsson, L. M. de la Maza, and E. M. Peterson. 2006. Growth inhibition of Chlamydiaceae by a putative type three secretion inhibitor, p. 245-248. In M. Chernesky, H. Caldwell, G. Christiansen, I. Clarke, B. Kaltenboeck, C. Knirsch, C.-C. Kuo, I. Mahony, R. Rank, P. Saikku, I. Schachter, W. Stamm, R. Stephens, I. Summersgill, P. Timms, and P. Wyrick (ed.), Chlamydial infections. Proceedings of the Eleventh International Symposium on Human Chlamydial Infections. International Chlamydia Symposium, San Francisco, CA.
29. Slepenkin, A., V. Motin, L. M. de la Maza, and E. M. Peterson. 2003. Temporal expression of type III secretion genes of Chlamydia pneumoniae. Infect. Immun. 71:2555-2562.
30. Stephens, R. S., S. Kalman, C. Lammel, J. Fan, R. Marathe, L. Aravind, W. Mitchell, L. Olinger, R. L. Tatusov, Q. Zhao, E. V. Koonin, and R. W. Davis. 1998. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 282:754-759.
31. Subtil, A., A. Blocker, and A. Dautry-Varsat. 2000. Type III secretion system in Chlamydia species: identified members and candidates. Microbes Infect. 2:367-369.
32. Subtil, A., C. Parsot, and A. Dautry-Varsat. 2001. Secretion of predicted Inc proteins of Chlamydia pneumoniae by a heterologous type III machinery. Mol. Microbiol. 39:792-800.
33. Wolf, K., H. J. Betts, B. Chellas-Gery, S. Hower, C. N. Linton, and K. A. Fields. 2006. Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol. Microbiol. 61:1543-1555.